The FDA decides today — August 5 — whether to approve Moderna's mRNA flu vaccine, mFlusiva. The FDA's expert advisory panel voted 9-0 on June 18 to recommend the shot for adults 50 and older. If the FDA approves it, mFlusiva would be the first mRNA seasonal flu vaccine in the United States. Getting here was turbulent: in February, FDA officials refused to even file Moderna's application, then reversed course eight days later on February 18.

1. The Trial Data Supports Approval (Moderna, Stanley Perlman at the University of Iowa)

A 9-0 expert vote says the shot works and the mRNA platform makes flu vaccines faster — approve it.

mFlusiva beat standard flu vaccines in every key measure the trial tracked. The Phase 3 trial enrolled more than 40,000 adults across 11 countries and found 26.6% relative efficacy against influenza-like illness versus standard-dose comparators, with 47.9% relative efficacy against severe outcomes like hospitalizations and ER visits. "The data were very convincing. Putting it all together, the benefits outweigh the problems," said Stanley Perlman, an infectious disease specialist at the University of Iowa and a member of the FDA's advisory panel. Nine of nine scientists voted yes.

mRNA flu vaccines update far faster than egg-based shots. Traditional flu vaccines grow the virus in fertilized chicken eggs, a six-month process. As the virus replicates inside the egg, it can mutate — drifting away from the strain actually circulating. An mRNA vaccine can compress that window to two or three months once scientists identify a new strain. "We had talked to the FDA at every step along the way — and they had said, you can go forward," Moderna president Stephen Hoge said about the February rejection.

2. One Season of Data Isn't Enough (HHS Secretary Robert F. Kennedy Jr.)

The administration canceled $500 million in mRNA vaccine research and says the platform's flu benefits are unproven.

The federal government cut mRNA vaccine research funding before today's decision. In August 2025, HHS canceled 22 contracts worth roughly $500 million in mRNA vaccine development. Health Secretary Robert F. Kennedy Jr. said the department had determined "mRNA technology poses more risks than benefits for these respiratory viruses." He had also canceled the federal flu awareness campaign and weakened recommendations for childhood flu shots.

The trial left real questions unanswered. Moderna tested mFlusiva in only one flu season. The trial had limited data on the influenza B/Victoria strain. It also excluded frail older adults and immunocompromised patients — the highest-risk groups. Even a supportive panel member flagged the limits: "We did miss an opportunity to really understand the performance of the product pre-licensure," said Dr. Hana El Sahly, a microbiologist at Baylor College of Medicine.

Side effects are also higher with mFlusiva. Nearly two-thirds of recipients (65.8%) reported injection-site pain — about twice the rate standard flu shots produce (29.8%). Fatigue hit 45%, headache 38%. All of it resolved within days. Still, the higher side-effect rate gives skeptics reason to argue that real-world uptake could suffer.

3. Approval Alone Won't Get Seniors a Free Shot (American Academy of Pediatrics, Rena Conti at Boston University)

Even if the FDA approves it today, the committee that triggers insurance coverage is legally paralyzed — and that's a separate problem no FDA decision resolves.

FDA approval and insurance coverage are two different things. Under the Affordable Care Act, insurers must cover vaccines at no out-of-pocket cost only when the CDC's Advisory Committee on Immunization Practices — ACIP — recommends them. ACIP can't currently recommend anything.

RFK Jr. fired all 17 ACIP members in June 2025, and a federal court froze his replacements. A Massachusetts federal judge blocked his 13 new appointees in March 2026 for violating federal law. ACIP has had no functioning quorum since, and can't hold meetings. Andrew Racine, president of the American Academy of Pediatrics, said the government "has had and continues to have the power to restore a lawful ACIP and schedule a meeting at any time."

Americans 65 and older are most exposed to that gap. They account for roughly 90% of annual flu deaths in the U.S. They're also the group the FDA would approve mFlusiva for, under an accelerated pathway that already requires a follow-up study. Without an ACIP recommendation, they'd face costs that patients getting standard flu shots under Medicare don't. Rena Conti, a health economist at Boston University, warned that FDA regulatory whiplash is compounding the problem: manufacturers "don't want to spend money if they don't think there's going to be a way to actually make money."

Where This Lands

Public health advocates say the FDA should approve mFlusiva today. The trial data is solid, the expert vote was unanimous, and mRNA vaccines update far faster than traditional ones. The MAHA camp argues one flu season of data doesn't prove a new technology. The administration already acted on that view by cutting $500 million in mRNA research funding. And there's a third problem. FDA approval can't fix the ACIP paralysis — and without a coverage recommendation, the seniors who need mFlusiva most would still have to pay for it themselves.

Sources